دورية أكاديمية
أعرض في EDS

TRIM5α restricts poxviruses and is antagonized by CypA and the viral protein C6.

التفاصيل البيبلوغرافية
العنوان: TRIM5α restricts poxviruses and is antagonized by CypA and the viral protein C6.
المؤلفون: Zhao Y; Department of Pathology, University of Cambridge, Cambridge, UK.; Sir William Dunn School of Pathology, University of Oxford, Oxford, UK., Lu Y; Department of Pathology, University of Cambridge, Cambridge, UK.; Sir William Dunn School of Pathology, University of Oxford, Oxford, UK., Richardson S; The Pirbright Institute, Surrey, UK., Sreekumar M; Department of Pathology, University of Cambridge, Cambridge, UK., Albarnaz JD; Department of Pathology, University of Cambridge, Cambridge, UK. jd732@cam.ac.uk.; Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK. jd732@cam.ac.uk., Smith GL; Department of Pathology, University of Cambridge, Cambridge, UK. geoffrey.smith@path.ox.ac.uk.; Sir William Dunn School of Pathology, University of Oxford, Oxford, UK. geoffrey.smith@path.ox.ac.uk.; The Pirbright Institute, Surrey, UK. geoffrey.smith@path.ox.ac.uk.; Chinese Academy of Medical Sciences-Oxford Institute, University of Oxford, Oxford, UK. geoffrey.smith@path.ox.ac.uk.
المصدر: Nature [Nature] 2023 Aug; Vol. 620 (7975), pp. 873-880. Date of Electronic Publication: 2023 Aug 09.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE
أسماء مطبوعة: Publication: Basingstoke : Nature Publishing Group
Original Publication: London, Macmillan Journals ltd.
مواضيع طبية MeSH: Antiviral Restriction Factors*/metabolism , Cyclophilin A*/metabolism , Poxviridae*/metabolism , Tripartite Motif Proteins*/metabolism , Ubiquitin-Protein Ligases*/metabolism , Viral Proteins*/metabolism, Humans ; Antiviral Agents/metabolism ; Capsid Proteins/metabolism ; Cell Line ; Proteasome Endopeptidase Complex/metabolism
مستخلص: Human tripartite motif protein 5α (TRIM5α) is a well-characterized restriction factor for some RNA viruses, including HIV 1-5 ; however, reports are limited for DNA viruses 6,7 . Here we demonstrate that TRIM5α also restricts orthopoxviruses and, via its SPRY domain, binds to the orthopoxvirus capsid protein L3 to diminish virus replication and activate innate immunity. In response, several orthopoxviruses, including vaccinia, rabbitpox, cowpox, monkeypox, camelpox and variola viruses, deploy countermeasures. First, the protein C6 binds to TRIM5 via the RING domain to induce its proteasome-dependent degradation. Second, cyclophilin A (CypA) is recruited via interaction with the capsid protein L3 to virus factories and virions to antagonize TRIM5α; this interaction is prevented by cyclosporine A (CsA) and the non-immunosuppressive derivatives alisporivir and NIM811. Both the proviral effect of CypA and the antiviral effect of CsA are dependent on TRIM5α. CsA, alisporivir and NIM811 have antiviral activity against orthopoxviruses, and because these drugs target a cellular protein, CypA, the emergence of viral drug resistance is difficult. These results warrant testing of CsA derivatives against orthopoxviruses, including monkeypox and variola.
(© 2023. The Author(s).)
References: Chiramel, A. I. et al. TRIM5α restricts flavivirus replication by targeting the viral protease for proteasomal degradation. Cell Rep. 27, 3269–3283.e6 (2019). (PMID: 31189110866614010.1016/j.celrep.2019.05.040)
Stremlau, M. et al. The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature 427, 848–853 (2004). (PMID: 1498576410.1038/nature02343)
Jimenez-Guardeno, J. M., Apolonia, L., Betancor, G. & Malim, M. H. Immunoproteasome activation enables human TRIM5α restriction of HIV-1. Nat. Microbiol. 4, 933–940 (2019). (PMID: 30886358654454410.1038/s41564-019-0402-0)
Kim, K. et al. Cyclophilin A protects HIV-1 from restriction by human TRIM5α. Nat. Microbiol. 4, 2044–2051 (2019). (PMID: 31636416687985810.1038/s41564-019-0592-5)
Selyutina, A. et al. Cyclophilin A prevents HIV-1 restriction in lymphocytes by blocking human TRIM5α binding to the viral core. Cell Rep. 30, 3766–3777.e6 (2020). (PMID: 32187548736300010.1016/j.celrep.2020.02.100)
Huang, H. H. et al. TRIM5α promotes ubiquitination of Rta from Epstein–Barr virus to attenuate lytic progression. Front. Microbiol. 7, 2129 (2016). (PMID: 28105027)
Lin, L. T. et al. Regulation of Epstein–Barr virus minor capsid protein BORF1 by TRIM5α. Int. J. Mol. Sci. https://doi.org/10.3390/ijms232315340 (2022).
Smith, G. L. et al. Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity. J. Gen. Virol. 94, 2367–2392 (2013). (PMID: 2399916410.1099/vir.0.055921-0)
Moss, B. & Smith, G. L. in Fields Virology: DNA Viruses Vol. 2 (eds Howley, P. M. & Knipe, D. M.) 573–613 (Wolters Kluwer, 2021).
Soday, L. et al. Quantitative temporal proteomic analysis of vaccinia virus infection reveals regulation of histone deacetylases by an interferon antagonist. Cell Rep. 27, 1920–1933.e7 (2019). (PMID: 31067474651887310.1016/j.celrep.2019.04.042)
Lu, Y. et al. Histone deacetylase 4 promotes type I interferon signaling, restricts DNA viruses, and is degraded via vaccinia virus protein C6. Proc. Natl Acad. Sci. USA 116, 11997–12006 (2019). (PMID: 31127039657520710.1073/pnas.1816399116)
Symons, J. A., Alcami, A. & Smith, G. L. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81, 551–560 (1995). (PMID: 775810910.1016/0092-8674(95)90076-4)
Kotwal, G. J. & Moss, B. Analysis of a large cluster of nonessential genes deleted from a vaccinia virus terminal transposition mutant. Virology 167, 524–537 (1988). (PMID: 2849238)
Graham, S. C. et al. Vaccinia virus proteins A52 and B14 share a Bcl-2-like fold but have evolved to inhibit NF-κB rather than apoptosis. PLoS Pathog. 4, e1000128 (2008). (PMID: 18704168249487110.1371/journal.ppat.1000128)
Stuart, J. H., Sumner, R. P., Lu, Y., Snowden, J. S. & Smith, G. L. Vaccinia virus protein C6 inhibits type I IFN signalling in the nucleus and binds to the transactivation domain of STAT2. PLoS Pathog. 12, e1005955 (2016). (PMID: 27907166513189810.1371/journal.ppat.1005955)
Unterholzner, L. et al. Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7. PLoS Pathog. 7, e1002247 (2011). (PMID: 21931555316954810.1371/journal.ppat.1002247)
Diaz-Griffero, F. et al. Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5. Virology 349, 300–315 (2006). (PMID: 1647283310.1016/j.virol.2005.12.040)
Fletcher, A. J. et al. Trivalent RING assembly on retroviral capsids activates TRIM5 ubiquitination and innate immune signaling. Cell Host Microbe 24, 761–775.e6 (2018). (PMID: 30503508629921010.1016/j.chom.2018.10.007)
Yamauchi, K., Wada, K., Tanji, K., Tanaka, M. & Kamitani, T. Ubiquitination of E3 ubiquitin ligase TRIM5α and its potential role. FEBS J. 275, 1540–1555 (2008). (PMID: 1831241810.1111/j.1742-4658.2008.06313.x)
Cooray, S. et al. Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. J. Gen. Virol. 88, 1656–1666 (2007). (PMID: 17485524288561910.1099/vir.0.82772-0)
Chen, R. A., Ryzhakov, G., Cooray, S., Randow, F. & Smith, G. L. Inhibition of IκB kinase by vaccinia virus virulence factor B14. PLoS Pathog. 4, e22 (2008). (PMID: 18266467223367210.1371/journal.ppat.0040022)
Carter, G. C. et al. Vaccinia virus cores are transported on microtubules. J. Gen. Virol. 84, 2443–2458 (2003). (PMID: 1291746610.1099/vir.0.19271-0)
Battivelli, E. et al. Modulation of TRIM5α activity in human cells by alternatively spliced TRIM5 isoforms. J. Virol. 85, 7828–7835 (2011). (PMID: 21632761314794210.1128/JVI.00648-11)
Li, X. & Sodroski, J. The TRIM5α B-box 2 domain promotes cooperative binding to the retroviral capsid by mediating higher-order self-association. J. Virol. 82, 11495–11502 (2008). (PMID: 18799578258365010.1128/JVI.01548-08)
Yap, M. W., Nisole, S. & Stoye, J. P. A single amino acid change in the SPRY domain of human Trim5α leads to HIV-1 restriction. Curr. Biol. 15, 73–78 (2005). (PMID: 1564936910.1016/j.cub.2004.12.042)
Castro, A. P., Carvalho, T. M., Moussatche, N. & Damaso, C. R. Redistribution of cyclophilin A to viral factories during vaccinia virus infection and its incorporation into mature particles. J. Virol. 77, 9052–9068 (2003). (PMID: 1288592116723010.1128/JVI.77.16.9052-9068.2003)
Damaso, C. R. & Keller, S. J. Cyclosporin A inhibits vaccinia virus replication in vitro. Arch. Virol. 134, 303–319 (1994). (PMID: 812961810.1007/BF01310569)
Damaso, C. R. & Moussatche, N. Inhibition of vaccinia virus replication by cyclosporin A analogues correlates with their affinity for cellular cyclophilins. J. Gen. Virol. 79, 339–346 (1998). (PMID: 947261810.1099/0022-1317-79-2-339)
Clipstone, N. A. & Crabtree, G. R. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357, 695–697 (1992). (PMID: 137736210.1038/357695a0)
Fruman, D. A., Klee, C. B., Bierer, B. E. & Burakoff, S. J. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc. Natl Acad. Sci. USA 89, 3686–3690 (1992). (PMID: 137388752555510.1073/pnas.89.9.3686)
Liu, J. et al. Calcineurin is a common target of cyclophilin–cyclosporin A and FKBP–FK506 complexes. Cell 66, 807–815 (1991). (PMID: 171524410.1016/0092-8674(91)90124-H)
Ohkura, S., Yap, M. W., Sheldon, T. & Stoye, J. P. All three variable regions of the TRIM5α B30.2 domain can contribute to the specificity of retrovirus restriction. J. Virol. 80, 8554–8565 (2006). (PMID: 16912305156389010.1128/JVI.00688-06)
Stremlau, M. et al. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5α restriction factor. Proc. Natl Acad. Sci. USA 103, 5514–5519 (2006). (PMID: 16540544145938610.1073/pnas.0509996103)
Stremlau, M., Perron, M., Welikala, S. & Sodroski, J. Species-specific variation in the B30.2(SPRY) domain of TRIM5α determines the potency of human immunodeficiency virus restriction. J. Virol. 79, 3139–3145 (2005). (PMID: 1570903354844710.1128/JVI.79.5.3139-3145.2005)
Resch, W. & Moss, B. The conserved poxvirus L3 virion protein is required for transcription of vaccinia virus early genes. J. Virol. 79, 14719–14729 (2005). (PMID: 16282472128755210.1128/JVI.79.23.14719-14729.2005)
Li, X., Yeung, D. F., Fiegen, A. M. & Sodroski, J. Determinants of the higher order association of the restriction factor TRIM5α and other tripartite motif (TRIM) proteins. J. Biol. Chem. 286, 27959–27970 (2011). (PMID: 21680743315104110.1074/jbc.M111.260406)
Li, Y. L. et al. Primate TRIM5 proteins form hexagonal nets on HIV-1 capsids. eLife https://doi.org/10.7554/eLife.16269 (2016).
Wagner, J. M. et al. Mechanism of B-box 2 domain-mediated higher-order assembly of the retroviral restriction factor TRIM5α. eLife https://doi.org/10.7554/eLife.16309 (2016).
Pertel, T. et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 472, 361–365 (2011). (PMID: 21512573308162110.1038/nature09976)
Tareen, S. U. & Emerman, M. Human Trim5α has additional activities that are uncoupled from retroviral capsid recognition. Virology 409, 113–120 (2011). (PMID: 2103516210.1016/j.virol.2010.09.018)
Zydowsky, L. D. et al. Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition. Protein Sci. 1, 1092–1099 (1992). (PMID: 1338979214218210.1002/pro.5560010903)
Sumner, R. P., Ren, H., Ferguson, B. J. & Smith, G. L. Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators. Vaccine 34, 4827–4834 (2016). (PMID: 27544585502240210.1016/j.vaccine.2016.08.002)
Sumner, R. P., Ren, H. & Smith, G. L. Deletion of immunomodulator C6 from vaccinia virus strain Western Reserve enhances virus immunogenicity and vaccine efficacy. J. Gen. Virol. 94, 1121–1126 (2013). (PMID: 23288427370958610.1099/vir.0.049700-0)
Lawitz, E. et al. Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy. Antiviral Res. 89, 238–245 (2011). (PMID: 2125561010.1016/j.antiviral.2011.01.003)
Zeuzem, S. et al. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naive patients with chronic HCV genotype 1 infection (ESSENTIAL II). Aliment. Pharmacol. Ther. 42, 829–844 (2015). (PMID: 2623870710.1111/apt.13342)
Albarnaz, J. D. et al. Molecular mimicry of NF-κB by vaccinia virus protein enables selective inhibition of antiviral responses. Nat. Microbiol. 7, 154–168 (2022). (PMID: 3494982710.1038/s41564-021-01004-9)
Zhang, R. Y., Pallett, M. A., French, J., Ren, H. & Smith, G. L. Vaccinia virus BTB-Kelch proteins C2 and F3 inhibit NF-κB activation. J. Gen. Virol. https://doi.org/10.1099/jgv.0.001786 (2022).
Blasco, R. & Moss, B. Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein. J. Virol. 65, 5910–5920 (1991). (PMID: 192062025025410.1128/jvi.65.11.5910-5920.1991)
Smith, G. L., Vanderplasschen, A. & Law, M. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol. 83, 2915–2931 (2002). (PMID: 1246646810.1099/0022-1317-83-12-2915)
Lederman, E. R. et al. Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. J. Infect. Dis. 206, 1372–1385 (2012). (PMID: 22904336352960310.1093/infdis/jis510)
Smith, T. G. et al. Resistance to anti-orthopoxviral drug tecovirimat (TPOXX®) during the 2022 mpox outbreak in the US. Preprint at medRxiv https://doi.org/10.1101/2023.05.16.23289856 (2023).
Fassbender, P. et al. Generalized cowpox virus infection in a patient with HIV, Germany, 2012. Emerg. Infect. Dis. 22, 553–555 (2016). (PMID: 26891134476688810.3201/eid2203.151158)
McSharry, B. P., Jones, C. J., Skinner, J. W., Kipling, D. & Wilkinson, G. W. G. Human telomerase reverse transcriptase-immortalized MRC-5 and HCA2 human fibroblasts are fully permissive for human cytomegalovirus. J. Gen. Virol. 82, 855–863 (2001). (PMID: 1125719110.1099/0022-1317-82-4-855)
Moss, B., Winters, E. & Cooper, J. A. Deletion of a 9,000-base-pair segment of the vaccinia virus genome that encodes nonessential polypeptides. J. Virol. 40, 387–395 (1981). (PMID: 627509525663910.1128/jvi.40.2.387-395.1981)
Maluquer de Motes, C., Schiffner, T., Sumner, R. P. & Smith, G. L. Vaccinia virus virulence factor N1 can be ubiquitylated on multiple lysine residues. J. Gen. Virol. 95, 2038–2049 (2014). (PMID: 24914067413509110.1099/vir.0.065664-0)
Alcami, A. & Smith, G. L. Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J. Virol. 69, 4633–4639 (1995). (PMID: 760902718926410.1128/jvi.69.8.4633-4639.1995)
Gloeckner, C. J., Boldt, K., Schumacher, A., Roepman, R. & Ueffing, M. A novel tandem affinity purification strategy for the efficient isolation and characterisation of native protein complexes. Proteomics 7, 4228–4234 (2007). (PMID: 1797917810.1002/pmic.200700038)
Chen, R. A., Jacobs, N. & Smith, G. L. Vaccinia virus strain Western Reserve protein B14 is an intracellular virulence factor. J. Gen. Virol. 87, 1451–1458 (2006). (PMID: 1669090910.1099/vir.0.81736-0)
Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731–740 (2016). (PMID: 2734871210.1038/nmeth.3901)
Ma, J. et al. iProX: an integrated proteome resource. Nucleic Acids Res. 47, D1211–D1217 (2019). (PMID: 3025209310.1093/nar/gky869)
Lu, Y., Michel, H. A., Wang, P. H. & Smith, G. L. Manipulation of innate immune signaling pathways by SARS-CoV-2 non-structural proteins. Front. Microbiol. 13, 1027015 (2022). (PMID: 36478862972029710.3389/fmicb.2022.1027015)
معلومات مُعتمدة: United Kingdom WT_ Wellcome Trust
المشرفين على المادة: 0 (Antiviral Agents)
0 (Antiviral Restriction Factors)
0 (Capsid Proteins)
EC 5.2.1.- (Cyclophilin A)
EC 2.3.2.27 (TRIM5 protein, human)
0 (Tripartite Motif Proteins)
EC 2.3.2.27 (Ubiquitin-Protein Ligases)
0 (Viral Proteins)
EC 3.4.25.1 (Proteasome Endopeptidase Complex)
تواريخ الأحداث: Date Created: 20230809 Date Completed: 20230826 Latest Revision: 20230904
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10447239
DOI: 10.1038/s41586-023-06401-0
PMID: 37558876
قاعدة البيانات: MEDLINE
الوصف
تدمد:1476-4687
DOI:10.1038/s41586-023-06401-0